Skip to content

Relevance of Biomarkers in the Process of Weaning

The Relevance of Biochemical Markers in the Process of Weaning

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01341561
Enrollment
100
Registered
2011-04-25
Start date
2011-04-30
Completion date
2013-04-30
Last updated
2011-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duration of Weaning

Brief summary

The purpose of the study is to examine the relevance of biochemical markers (specific pulmonary and cardiac markers and markers of endogenous stress) in the process of weaning in patients with artificial ventilation.

Detailed description

Artificially ventilated patients on our intensive care unit will be monitored if specific biomarkers have a relevance in risk stratification, optimizing therapy, outcome and success in the process of weaning. Therefore, consecutively, specific blood parameters will be taken at time of intubation,day 1 of weaning and extubation.

Interventions

None listed

Sponsors

Heidelberg University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Able and willing to understand the protocol * At least 18 years or older

Exclusion criteria

* Not fulfilling inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
success of weaningparticipants will be followed for the duration of hospital stay, an expected average of 30daysprimary outcome measure is the success of weaning during hospital stay. Duration of hospital stay is estimated between 1-60days, in average 30days. Criteria is spontaneous breathing.

Secondary

MeasureTime frameDescription
follow up12 monthsFollow up is done after 12 months to check major adverse cardiac or pulmonary events (death, myocardial infarction, re-hospitalisation)

Countries

Germany

Contacts

Primary ContactEvangelos Giannitsis, Prof. Dr.
Evangelos_Giannitsis@med.uni-heidelberg.de0049-6221-56-38686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026